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ABSTRACT
Allogeneic stem cell transplantation (Allo-SCT) remains an option for patients with follicular lymphoma (FL).
We performed a retrospective analysis to examine long-term disease control and treatment-related mortality
(TRM) in a group of patients that underwent transplant for clinically high-risk disease. Thirty-seven patients
with indolent FL (follicular small cleaved [FSC], follicular mixed [FM] or FL grades 1 or 2 byWHO criteria) un-
derwent allo-SCT. Patients were in a chemosensitive remission at the time of SCT. The conditioning regimen
was typically busulfan-cyclophosphamide (BuCy). Cyclophosphamide-total body irradiation (TBI) was used for
unrelated donor SCT.Themedian age at the time of transplant was 45 years (range: 24-58). Themedian number
of prior chemotherapy regimens was 3 (range: 1-6). Thirty-seven patients received BuCy conditioning and 2 pa-
tients underwent reduced intensity conditioning SCT. Seventy-two percent of patients had a matched sibling
donor.With amedian follow-up of 63.5months in survivors, the 5-year overall survival is 79.1% (95% confidence
interval 66.3%-94.4%). TRM was 15.4%, with an additional case of mortality from breast cancer. These results
demonstrate that in selected younger patients, a fully myeloablative allo-SCT utilizing BuCy conditioning pro-
vides excellent OS and disease control with low TRM.
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Although patients with follicular lymphoma (FL)
may achieve long remission durations with current
therapies, it remains unlikely that these are curative
strategies [1,2]. Recent innovations including combi-
nation immunochemotherapy and maintenance with
the anti-CD20 monoclonal antibody (mAb) rituximab
have demonstrated an improved progression-free
(PFS) and overall survival (OS) in patients with FL
[3-6]. Despite the advent of immunochemotherapy-
based strategies, stem cell transplantation (SCT)
approaches remains an attractive option in the
management of FL for several reasons.Dose-intensive chemotherapy has been demon-
strated to improve PFS and OS in the relapsed
lymphoma setting with the use of autografts to amelio-
rate the hematologic toxicity of high-dose chemother-
apy [7,8]. Tumor graft contamination as part of an
SCT procedure can be reduced through the use of
purging strategies in the autologous setting (although
the benefit of this remains a debatable point given the
inconsistent published results) or eliminated through
the use of syngeneic or allogeneic stem cells from
a healthy donor [8-12]. Donor-derived SCT offers
the additional benefit of a potential immunologically
mediated graft-versus-lymphoma (GVL) effect that775
776 J. Kuruvilla et al.could provide sustained immune surveillance and
reduced rate of lymphoma recurrence in the recipient.
The evidence of a GVL effect has been indirectly
suggested based on a reduction in the rate of relapse
in patients undergoing allogeneic SCT (allo-SCT)
when compared to autologous SCT (ASCT), but the
significance of this effect remains in question, as this
has never been tested in a randomized trial [13-16].
Further direct evidence of a GVL effect has been
demonstrated through the use of donor lymphocyte
infusion (DLI), which may induce remission in pa-
tients following allo-SCT [17-19].
ASCT for FL has been evaluated in the front-line
and relapsed setting, and has resulted in an improved
PFS when compared to anthracycline-based chemo-
therapy [8,20-22]. The randomized European CUP
trial was the only study to demonstrate an OS advan-
tage for ASCT in a small group of patients with re-
lapsed FL [8]. Although ASCT has greater
applicability in FL (compared to myeloablative allo-
SCT) as it can be considered in patients up to age 65
or 70 years and may be performed with a relatively
low treatment-related mortality (TRM), data failed
to demonstrate a plateau in survival curves, and there
are concerns with secondary myelodysplasia and acute
leukemia [8,20-22].
Allo-SCT remains a potential curative strategy
because of the ability to provide dose intensity, a tu-
mor-free stem cell graft and GVL effect from the
donor immune system. Registry and single-center
reports have failed to clearly demonstrate these ad-
vantages, and these data remain difficult to interpret
because of sample size, patient selection, and study
heterogeneity [9,10,15,23-27]. Applicability also re-
mains a concern, as myeloablative SCT is generally
restricted to younger patients and TRM may be
high (particularly when considering unrelated donor
SCT). Newer reduced-intensity conditioning SCT
(RICSCT) techniques are appealing because they in-
crease the availability of allogeneic SCT procedures
by increasing the upper age limit, expanding the
limit of organ function and comorbidity, and appear
to reduce early TRM [19,23,25,27,28]. However,
RICSCT needs to be evaluated carefully because
the benefits must be weighed against the reduction
in dose intensity (and thus tumor control) that
the procedure affords. Early registry data from the
Center for International Bone Marrow Transplant
Research (CIBMTR) demonstrates relapse rates in
FL may be increased in patients undergoing
RICSCT [27].
We reviewed our experience of allo-SCT for indo-
lent FL. Previously, we have demonstrated favorable
results in a cohort of non-Hodgkin lymphoma
(NHL) patients with varying histology treated with
a busulfan-basedpreparative regimen [24].The current
analysis was confined to confirmed indolent FL, and re-ports results of longer follow-up of over 5 years in a co-
hort of patients treated with myeloablative allo-SCT.
PATIENTS AND METHODS
Study Design, Patient Evaluation, and Eligibility
We evaluated 37 consecutive patients with FL who
underwent myeloablative allo-SCT at Princess Mar-
garetHospital between January 1, 1989, andDecember
31, 2005. All patients had a biopsy proved histologic di-
agnosis of FL (follicular small cleaved or follicular
mixed by the REAL classification or follicular grade
1 or follicular grade 2 by the WHO classification). If
serial biopsies were available, there were no biopsies
that showed evolution to FL grade 3 (follicular large
cell lymphoma) or of transformation to diffuse large
B cell lymphoma. Data were obtained from a prospec-
tively collected database, and additional information
was collected from computerized records or patient
charts as required. The Princess Margaret Hospital
Research Ethics Board and Cancer Registry Data
Access Committee (CRDAC) approved this study.
Patients were eligible to receive allo-SCT if they
had a histologic diagnosis of FL as above and had re-
ceived at least 1 prior chemotherapy regimen (typically
cyclophosphamide, doxorubicin, vincristine and pred-
nisone [CHOP]), and were high risk (multiple lines of
chemotherapy, short remission duration with prior
therapy, prior ASCT, ineligible for ASCT because of
lack of adequate stem cell collection, persistent bone
marrow involvement), along with appropriate donor
availability (matched sibling, syngeneic, or unrelated)
and patient and physician preference. Tumor biopsy
was not required at the time of disease relapse or pro-
gression unless there was concern of transformation to
aggressive histology NHL. Each chemotherapy
regimen was given as is typical for advanced stage FL
(6-8 cycles of CHOP, $4 cycles of fludarabine (Flu)-
based regimens, 4 courses of single agent rituximab
unless there was obvious evidence of disease progres-
sion). Transplantation was not offered if the patient
had evidence of chemotherapy-refractory lymphoma.
Patients were eligible for allo-SCT if they had at
least a stable disease response to chemotherapy prior
to transplant (and had no bulky sites of disease), were
$18 years of age, and had an Eastern Cooperative
Oncology Group performance status of 0-2 at the
time of allo-SCT [29]. Patients were restaged at the
time of relapse or progression with computed tomog-
raphy (CT) of chest, abdomen, and pelvis and mag-
netic resonance imaging (MRI), when appropriate.
Gallium scans were recommended but were not re-
quired. Positron emission tomography scans were
not performed. Baseline blood tests included a com-
plete blood count, lactate dehydrogenase, liver enzyme
tests, albumin, and serum creatinine. Bone marrow as-
pirate and biopsy was required prior to allo-SCT and
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lymphoma as long as some chemosensitivity had been
demonstrated. Patients were ineligible if they had un-
controlled infection or significant organ dysfunction
that would preclude SCT. Disease response to chemo-
therapy was retrospectively categorized according to
the International Working Group Criteria [30].
Conditioning Regimen and BMT Procedure
The preparative regimen consisted of either oral
Bu in (1989-2000: 4 mg/kg orally in 4 daily divided
doses for 4 days for a total of 16 mg/kg) or intravenous
Bu in (2001-2005: 3.2 mg/kg i.v. daily for 4 days) fol-
lowed by intravenous cyclophosphamide (Cy) 60 mg/
kg administered daily for 2 days (total dose of 120
mg/kg). Phenytoin was administered as prophylaxis
for Bu-induced seizures. One patient received Cy 60
mg/kg intravenously administered daily for 2 days (to-
tal dose 120 mg/kg) with total body irradiation (TBI)
12 Gy in 6 fractions and underwent SCT from an
unrelated donor.
GVHD Prophylaxis and Supportive Care
Standard cyclosporine (CSA) and methotrexate
(MTX) were used for GVHD prophylaxis. Patients
undergoing syngeneic transplantation received an ab-
breviated course of cyclosporine A at a dose of 1 mg/
kg for 28 days in an attempt to induce a GVL effect.
Patients were transplanted in isolation rooms. An-
tiviral prophylaxis included acyclovir 200 mg orally
twice a day or 80 mg i.v. twice a day every 12 hours
from days 1-28. Trimethoprim/sulfamethoxazole 2
tablets orally twice a day or an equivalent i.v. dose
was employed starting from the day of hospital ad-
mission until neutrophil recovery. Trimethoprim/
sulfamethoxazole was used for Pneumocystis jiroveci
prophylaxis for 1 year post-allo-SCT or longer if pa-
tients remained on immunosuppression. Patients
with sulfa allergies or significant bone marrow sup-
pression received aerosolized pentamidine at a dose
of 300 mg every 2-4 weeks.
Red cell depletion of the donor bone marrow was
performed in the case of ABO-incompatible donor-re-
cipient pairs. None of the grafts were ex vivo T cell de-
pleted. Target cell doses were 3.0 108 total nucleated
cells/kg for marrow transplants and 5  106 CD341
cells/kg for peripheral blood stem cell transplants.
Preemptive screening for cytomegalovirus (CMV)
was performed since 1992 using day 135 bronchos-
copy or serial CMV antigenemia testing if either donor
or recipient was CMV positive. Patients with positive
CMV testing were treated with i.v. ganciclovir and in-
travenous immunoglobulin (IVIG) was used for pa-
tients with lung involvement.
Disease status was reassessed at between 3 and
6 months and 1 year posttransplant by repeat imagingand bone marrow aspirate and biopsy, or sooner
according to clinical signs or symptoms.
Statistical Methods and Definitions
Thirty-seven patients were diagnosed with FL/FM
between 1981 and 2003 and underwent BMT at Prin-
cess Margaret Hospital. Patient demographics were
summarized using descriptive statistics such as the
mean, standard deviation (SD), proportion, and fre-
quency. The Kaplan-Meier method was used for esti-
mating OS and PFS statistics [31]. Univariate Cox
proportional hazards regression was used to investi-
gate potential predictors of OS and PFS. Multivariate
methods were not performed because of the small
sample size. To account for the competing risk of non-
treatment-related death in the analysis of TRM, a com-
peting riskmodel was constructed which is adjusted for
non-treatment related deaths. All tests were 2-sided
and a P-value of .05 or less was considered statistically
significant.
Veno-occlusive disease (VOD) of the liver and
both acute and chronic graft-versus-host-disease
(aGVHD, cGVHD) were defined as per previously
published criteria [32-34]. For survival calculations,
patients alive at last follow-up were censored on the
date they were last confirmed alive, or alive and
progression-free for the PFS outcomes. Time to re-
lapse was evaluated from the date of BMT to the
date of confirmed relapse. Patients were censored if
they were alive and relapse-free at the date of last




Table 1 describes the patient demographics.
Twenty (51%) were male and the mean age at the
time of transplant was 44 with a range of 27 to 60 years.
The median time from diagnosis to allo-SCT was 25.5
months (range: 6.2-157.8 months) and the median
number of prior chemotherapy regimens was 3 (1-6).
All patients received chemotherapy and had at least
a stable disease response prior to allo-SCT. Twenty-
one percent received prior radiotherapy and 11%
had received prior rituximab. There were 4 patients
who underwent syngeneic transplant, 2 patients
who underwent allo-SCT from a matched unrelated
donor (MUD), and 5 patients were transplanted from
a 1-antigen mismatched-related donor.
Survival, Relapse, and TRM
The median follow-up for the entire cohort was
48.8 months, with the maximum follow-up of 192
months. Clinical outcomes are described in Table 2.
As of the last known follow-up, 1 patient was alive after
disease recurrence, 7 patients had died, and 31 were
778 J. Kuruvilla et al.alive with no evidence of disease. Of those who died, 6
were treatment-related (2 patients with bronchiolitis
obliterans, 1 patient with Pneumocystis jiroveci pneumo-
nia, 1 patient with multiorgan failure, 1 patient with
VOD and candida tropicalis infection, and 1 patient
Table 1. Patient Demographics
Characteristic N (%)
Age at Diagnosis








Number of Prior Regimens
1:2:3:4:5:6 4:10:13:4:5:1
Prior therapies
Prior Purine Analog 9 (24.3%)
Prior Alkyaltor 21 (56.8%)
Prior Anthracycline 34 (91.9%)
Prior Platinum 18 (48.7%)
Prior Rituximab 9 (24.3%)
Prior ASCT 1 (2.7%)
Prior Radiotherapy 7 (18.9%)
Time from Diagnosis to
BMT (months) 2 Median (range)
24.0 (6.2-148.6)
Age at BMT




Disease status at BMT
CR / CRu 11 (30%)
PR 22 (59%)
SD 3 (8%)
Resistant / Untested relapse 0
Unknown 1 (3%)
Donor Match
HLA-identical Sibling 27 (73.0%)
Mismatch Donor 5 (13.5%)
Matched Unrelated Donor 1 (2.7%)
Syngeneic Donor 4 (10.8%)
Graft Source
Bone Marrow 33 (89.2%)










Not applicable 2 (5.4%)
FL1 or FL2 indicates follicular lymphoma grade 1 or grade 2 by
WHO criteria; FSC or FM, follicular small cleaved or follicular
mixed by REAL classification; FL, indolent/low grade follicular
lymphoma unspecified (not grade 3 by WHO or follicular large
cell by REAL); Conditioning, see Conditioning Regimen and
BMT Procedure in Patients and Methods.with VOD and aGVHD) and the final death was
because of breast cancer. The sole patient who re-
lapsed has required therapy for indolent NHL and
and was not on therapy at the time of data analysis.
Five-year OS was estimated to be 79% (95% confi-
dence interval [CI]: 66%-94%, see Figure 1), 5-year
PFS was estimated to be 76% (95% CI: 63%-92%,
Figure 2), and 5-year TRM was 18% (95% CI: 5%-
31%, Figure 3).
aGVHD developed in 80% of cases (grade 3 in 5
cases and none with grade 4) whereas cGVHD devel-
oped in 54%. This was limited in 23% and extensive
in 31%.
Prognostic Factor Analysis
Univariate regression statistics for predictors of
survival, PFS, and TRM are in Table 3. Only age
was statistically significant (P \ .01) as a predictor
for each outcome.
DISCUSSION
Results of allo-SCT must always be considered in
the context of the disease being treated; FL remains
a disease with a typically indolent course that is chemo-
sensitive, and patients may enjoy long remissions after
therapies that may be intermittently applied over
a number of years. Although clinical factors such as
those in the FL International Prognostic Index
(FLIPI) may identify a high-risk group of patients
with a poor expected survival from diagnosis or at
relapse, these prognostic factor analyses have not in-
cluded therapy or remission duration as a factor [35].
Remission duration generally tends to shorten with
the application of second-line or subsequent therapies,
Table 2. Clinical Outcomes
Outcome Value
Follow-up (all)
Median (range) months 59.8 (0.4-192.7)
Follow-up (X survivors at last follow-up)
Median (range) months 64.8 (0.4-192.7)
Status at last follow-up
Alive in remission 29 (78.4%)
Alive after relapse 1 (2.7%)
Dead 7 (18.9%)
Overall Survival
Median (95% CI) Not Reached
1-year (95% CI) 91.5% (82.8%-100.0%)
5-year (95% CI) 78.7% (65.7%-94.2%)
Progression-Free Survival




Median (95% CI) Not Reached
1-year (95% CI) 8.5% (0.0%-17.8%)
5-year (95% CI) 18.2% (4.7%-31.7%)
Allogeneic SCT for FL 779and thus multiple lines of therapy tends to be a signifi-
cant factor in determining outcome as this is a marker
of presumed chemoresistance.
We chose to exclude follicular grade 3 lymphoma
(follicular large cell in the REAL classification), as
this entity has been traditionally included with ‘‘inter-
mediate grade’’ (aggressive histology) NHL, and con-
troversy regarding treatment approaches remains,
although there is an emphasis on anthracycline-based
chemotherapy [36]. The patients have a median age
of 44 (young for patients with FL), but patients were
fairly heavily pretreated (but chemosensitive at the
time of SCT) having received a median of 3 prior che-
motherapy regimens in a time frame from diagnosis to
allo-SCT of approximately 2 years. Rituximab had
been used in a prior regimen in 11% of patients.
Despite this extensive pretreatment, the observed
TRM was low at 15%; with a sample size of 39 cases,
the 95% CIs range from 5% to 31%, and suggest
that good results can be achieved in previously pre-
treated patients under the age of 60 with the applica-
tion of a myeloablative allo-SCT regimen. Our data
compares favorably with both single-institution and
registry series that estimate TRM in this setting to
range from 30% to 40% with mature follow-up
[9,10,14,26,37-39].
Figure 1. OS from date of allogeneic SCT.
Figure 2. PFS from date of allogeneic SCT.The favorable OS in the cohort may be explained
in large part because of a low rate of relapse and death
from lymphoma. A clear relationship between the ab-
sence of cGVHD and relapse could not be demon-
strated, likely related to the sample size and the fact
that we had few relapse events in the cohort. Even in
larger series with more events to analyze, a specific
relationship between the presence of cGVHD and
reduced relapse has not been clearly demonstrated
[9]. Thus, it is difficult to ascertain if the favorable
outcome seen in our series reflects efficacy of this
busulfan-based preparative regimen or the impact of
a GVL effect that could not be demonstrated because
of limitations in sample size and number of events.
Our results demonstrate that myeloablative SCT
can be performed safely in patients under the age of
60 years, and suggest that a TRM comparable to
RICSCT can be possible in a single center experience.
Recent data from the CIBMTR from a comparative
registry review of FL has shown that TRM (24% in
RICSCT versus 25% for myeloablative SCT) appears
similar, and an inferior relapse rate was present in the
RIC cohort (55%versus 65% at 3 years post-SCT) [27].
Allogeneic transplantation must be considered in
the context of other therapies employed for recurrent
disease. Randomized trials have evaluated different
chemotherapy strategies or chemotherapy compared
to ASCT in the setting of relapsed (typically second-
or third-line treatment) lymphoma. The EORTC
and GLSG randomized trials of immunochemother-
apy and maintenance rituximab of R-CHOP report
3-year OSs of 77% to 85% in the rituximab mainte-
nance arm [6,40], whereas the randomized CUP
study reported 4-year OSs of 71% and 77% for the
unpurged and purged bone marrow groups that un-
derwent ASCT [8]. The sample sizes in these studies
range between 32 and 76 patients per arm, and are
Figure 3. Treatment-related mortality.
780 J. Kuruvilla et al.Table 3. Predictors of Progression Free Survival (PFS), Overall Survival (OS), and Treatment related Mortality (TRM)
PFS OS TRM
Predictor Hazards Ratio (95% CI) P-Value Hazards Ratio (95% CI) P-Value Hazards Ratio (95%CI) P-Value
Age at BMT 1.15 (1.04-1.27) .008 1.17 (1.04-1.31) .008 1.20 (1.11-1.31) \.001
Diagnosis 5 FL/FM 1.50 (0.36-6.29) .58 1.20 (0.27-5.36) .82 0.90 (0.18-4.42) .90
HLA-matched sibling donor 1.19 (0.24-5.88) .84 0.96 (0.19-4.96) .96 0.75 (0.15-3.88) .73
Acute GVHD 1.74 (0.21-14.13) .61 1.48 (0.18-12.33) .72 1.24 (0.15-10.35) .84
Chronic GVHD 1.39 (0.33-5.85) .65 1.09 (0.24-4.90) .91 0.81 (0.16-4.00) .80
$3 Prior therapies 6.02 (0.73-49.36) .095 4.93 (0.59-41.24) .14 3.94 (0.43-36.23) .23
Prior alkylator 1.33 (0.32-5.60) .70 1.04 (0.23-4.66) .96 0.76 (0.15-3.83) .74
Prior purine analog 1.19 (0.24-5.99) .83 0.56 (0.07-4.69) .59 0.70 (0.09-5.29) .73
Prior platinum 1.81 (0.43-7.58) .42 1.41 (0.32-6.31) .65 1.04 (0.22-5.03) .96
Prior rituximab 0.75 (0.09-6.14) .79 0.87 (0.10-7.34) .90 1.04 (0.13-8.64) .97
Prior XRT 4.05 (0.94-17.44) .060 2.34 (0.45-12.21) .31 2.96 (0.56-15.77) .20
Graft source 5 BM 0.56 (0.07-4.58) .59 0.48 (0.06-3.98) .48 0.39 (0.07-2.25) .30
BM indicates bonemarrow;GVHD, graft-versus-host-disease; BMT, bonemarrow transplant; FL, follicular lymphoma; FM, follicularmixed by
REAL classification.thus of similar size to our series. These studies report
similar results to our myeloablative allo-SCT series
and include less-pretreated patients with shorter
follow-up.
The strength of this study is the long follow-up
with of a median of over 5 years in survivors and
a low relapse rate that demonstrates no recurrences
after 4 years with ongoing follow-up now over 16 years
post-SCT. Clearly, athough this is a retrospective
single center cohort, these results demonstrate the
feasibility and efficacy of a transplantation strategy
that emphasizes myeloablative allo-SCT in patients
without refractory disease. Although RICSCT im-
proves the availability of allo-SCT procedures in this
field, myeloablative SCT should still be considered
in patients under the age of 60 yearswith amatched do-
nor (differences in survival outcomes with a small num-
ber of alternate donor transplants in this series could
not be demonstrated) and acceptable comorbidities.
Randomized trials are the cornerstone of the ther-
apy of FL and remain 1 the key factors in improving
OS in the disease [41,42]. Although the majority of
novel drugs (radioimmunotherapy, proteasome inhib-
itors, immunomodulatory agents, or histone deacety-
lase inhibitors) have yet to clearly define a role,
rituximab has become part of the standard of care at
the time of diagnosis, at relapse, and as a maintenance
agent. The integration of rituximab into allo-SCT
strategies remains an important area of research. It
has been demonstrated that rituximab can be given as
part of a preparative regimen safely and may also be
given after the transplant as a means of reducing
relapse, although this has not been tested in Phase
III trials [43,44]. The impact of rituximab on tumor
immunosurveillance and cGVHDwill need to be eval-
uated in prospective studies.
Allo-SCT is a therapy that will be used later in the
disease course, and given current clinical practice,
patients will have received multiple applications ofrituximab (with or without chemotherapy). Results
from carefully constructed prospective clinical trials
that focus on discrete patients groups with a common
histology will be required to allow allo-SCT to be-
come 1 of the standard options that are available to
patients with FL. Although RICSCT techniques im-
prove the availability of allo-SCT to patients with
FL in general, caution must be applied while interpret-
ing results with short follow-up, and consideration
should be given to more proved strategies such as
myeloablative allo-SCT in eligible patients.
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